Cocrystal Pharma posts Q2 net loss $5.3M, cash $18.1M; pipeline milestones set

Cocrystal Pharma, Inc.

2024-Q2 EPS reported -$0.91

Q2 2024 net loss $5.3M ($0.54/sh) vs Q2 2023 net loss $4.2M ($0.41/sh); R&D spend $4.3M up 54% YoY.
Cash $18.1M at June 30 from $26.4M at Dec 31; runway expected to fund operations for next 12 months.
Topline results from Phase 2a influenza A human challenge study (oral CC-42344) expected in 2025.
In vitro data shows CC-42344 inhibits avian influenza A (H5N1) PB2 protein recently found in U.S. dairy cows.
Topline Phase 1 results for pan-coronavirus/norovirus oral CDI-988 expected late 2024 / early 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.